生命科学资讯

The next generation is shaping the future of rare diseases - Illumina

The Analyst Verdict: Agilent Technologies In The Eyes Of 9 Experts - Benzinga

DOJ urges Supreme Court to undo revival of Hikma ‘skinny label’ case

Doug Ingram’s force of will meets its match as Sarepta CEO plans to depart

FDA probes internal Prasad complaints with outside help

Boehringer wins accelerated approval for first-line use of lung cancer drug

Sarepta CEO Doug Ingram to retire after a decade of Duchenne breakthroughs and controversies

Analysts see potential in MDMA drug after AtaiBeckley reports improvements in anxiety trial

Agilent Technologies (A) Sees Analyst Price Target Adjustment by UBS | A Stock News - GuruFocus

UBS Group Lowers Agilent Technologies (NYSE:A) Price Target to $165.00 - MarketBeat

Senate hearing raises FDA-related concerns for new rare disease drugs

Surprising partner preference found in matings between Neanderthals and modern humans

Illumina Announces NovaSeq X Performance Upgrades Including Q70 Quality Scores - Clinical Lab Products

Agilent Technologies shares fall after Q1 earnings miss - Investing.com

Viatris plans to lay off up to 10% of staff, discloses Indian factory fire

Did Thermo Fisher’s (TMO) 10% Dividend Hike After Earnings Beat Just Reframe Its Capital Return Story? - simplywall.st

Agilent Technologies (A): Wells Fargo Lowers Price Target to $16 - GuruFocus

THERMO FISHER SCIENTIFIC INC. SEC 10-K Report - TradingView

Lilly’s GLP-1 pill tops Novo’s Rybelsus in head-to-head trial

Why did my doctor push Grail’s dubious cancer test?